Full Professor in Chemistry, Department of Chemistry, Faculty of Mathematics and Natural Sciences, University of Prishtina “Hasan Prishtina”, Republic of Kosovo. Prof. Berisha leads the Materials Science - Nanochemistry Research Group under NanoAlb, an initiative of the Albanian Academy of Science, which fosters collaboration in nanoscience across Albania, Kosovo, North Macedonia, and Montenegro. His research is mainly focused on surface modification of materials through covalently grafted nanometric 2D organic layers, computational chemistry (DFT, MC MD and Molecular Docking), electrochemistry (with a focus on corrosion and sensors), and the adsorption of pollutants using nanostructured adsorbents. Prof. Berisha has authored over 208 scientific publications. With an h-index of 43 and more than 5,450 citations, his work has garnered significant international recognition. He has also contributed to numerous book chapters and led several scientific projects. His achievements have recently earned him a place in Stanford's Top 2% Scientist Rankings, underscoring his significant influence in the scientific community. He is actively involved in academic and scientific policy as a member of the State Council of Quality (SCQ) of the Kosovo Accreditation Agency (KAA). Additionally, he represents Kosovo on the Board of Governors of the Joint Research Centre (JRC) of the European Commission.

Armond Daci, Prof, PhD, is an Associate Professor of Pharmacology at the Faculty of Medicine, Department of Pharmacy. He teaches courses within PhD programs in preclinical and clinical medicine and serves as a Science Coordinator of the Faculty of Medicine at the University of Prishtina, Hasan Prishtina, Kosovo. Areas of research interest are Cardiovascular Pharmacology, Therapeutic Drug Monitoring, Drug Delivery and Pharmacogenetics. He has gained research experience during his PhD studies at the Center for Physiology and Pharmacology, Medical University of Vienna, Department of Pharmacology and Biomolecular Science, University of Milan, University of Milan. Department of Pharmacology, Istanbul University, and recently Post Doc Fellowship at the Department of Pharmacology and Toxicology, Michigan State University. He has contributed to national projects funded by MEST, and to international projects such as Erasmus Plus, SIGMA, TEMPUS, YTB, and Fulbright. Dr Daci has actively participated in international conferences at home and abroad. He is an author of 30 indexed scientific papers, (cited 670 times, h-index 14) and serves as a reviewer for many indexed scientific journals. He was awarded as Scientist of the Year from MEST and Kosovo Academy of Science, twice as best oral speaker and awarded for research based learning from QAINT and MEST project. He is sharing his experience by actively serving as a member of the commission established by the Ministry of Health for the evaluation of medical products at the National Agency for Medical Products and also he was a member of the Review for the First Clinical Guideline "Management and Treatment COVID-19". He is an active coordinator from UP, in the project Nanoparticles in Environment and Medical Research" - EUROPEAID/173691/DD/ACT/XK (“Increasing Research Capacities in Kosovo”).

Dr Ian Mudway is a senior lecturer in the School of Public Health at Imperial, a member of the MRC Centre for Environment and Health; MRC & Asthma UK Centre in Allergic Mechanisms of Asthma and the NIHR-PHE Health Protection Research Units in Environmental Exposures and Health and Chemical and Radiation Threats and Hazards.

Driton is currently a Reader at King’s College London. He is a registered pharmacist and gained his PhD at the University of Nottingham. Prior to joining King’s, Driton contributed towards the establishment of a new School of Pharmacy (University of Lincoln). Driton’s research interests centre around understanding and overcoming the biological barriers to improve drug delivery, with a key focus on enabling injection-free administration of biotherapeutic drugs (peptides, proteins, nucleic acids). As part of this, he has specific interests in drug delivery systems, including nanomedicines and exosomes, that potentially enable injection-free delivery. He is also interested in drug delivery for diseases of, or linked to, the gut. Finally, aspects of Driton’s research relate to the creation of improved (more predictive) in vitro models for use in medicines development, including organoids. Driton routinely collaborates with the pharmaceutical industry and his research has been funded by different UK Research and Innovation councils, charities and the pharmaceutical industry. He is currently leading the EU-funded ‘Nanoparticles in Environment and Medical Research’ (NanoKos) project. The overarching aim of Driton’s activity is to improve patient outcomes and access to medicines through translational drug delivery research.